Depressed Exercise Peak Ejection Rate Detected on Ambulatory Radionuclide Monitoring Reflects End-Stage Cardiac Inotropic Reserve and Predicts Mortality in Ischaemic Cardiomyopathy

Gian Piero Carboni

Abstract

Background: Fifteen patients with ischaemic cardiomyopathy and inducible ischaemia were studied to determine the mechanisms of mortality. Failure of the contractile reserve during daily life activities may reflect a prognostic index.

Methods: Single photon emission cardiac tomography and radionuclide ambulatory monitoring (Vest) data were analysed in all patients with a 7-year follow-up.

Results: At peak exercise on Vest, the 7 non-survivors (N-SURV) showed worse peak ejection rates (PERs) and ejection fractions (EFs) compared with the 8 survivors (SURV), (2 ± 0.6 vs. 3.3 ± 0.7; end-diastolic volumes (EDVs), P < 0.003), and (34 ± 10% vs. 50 ± 13%; P < 0.02), respectively. However, exercise peak filling rates (PFRs) (1.9 ± 0.6 vs. 2.7 ± 0.9; EDVs/s) and exercise heart rates (HRs), (97 ± 17 vs. 106 ± 10), did not differ between the two groups (P > 0.05). In SURV, exercise PERs, which represented rapid left ventricular (LV) emptying, were significantly correlated with exercise PFRs, representing rapid LV filling, (r = 0.71, P < 0.04) but not in N-SURV (r = 0.66, P > 0.05). Among SURV, the Frank-Starling mechanism was thus preserved but not in N-SURV. Upon Cox analysis, overall LV function parameters, exercise PER was the only predictive measure associated with mortality (b = - 0.018, relative hazard ratio = 0.98, P = 0.02).

Conclusions: Exercise PER reduced values reflected failure of the Frank-Starling mechanism, the incapacity of the heart to perform rapid contractile adaptations to daily life activities and a poor prognosis.

Keywords: Peak ejection rate; Ambulatory radionuclide monitoring; Vest; Ischaemic cardiomyopathy

Introduction

In patients with ischaemic cardiomyopathy (ICMP), survival is limited despite the improvements in revascularisation techniques, heart surgery and medical therapy. Yoon et al [1] observed that in ICMP patients who were treated with different therapeutic options, the 9-year survival was as follows: coronary artery bypass grafting, 53%; coronary artery bypass grafting plus mitral valve annuloplasty, 34%; coronary artery bypass grafting plus surgical ventricular restoration, 55%; listing for cardiac transplantation, 54%. There is, however, still a debate on the mechanism and incidence of mortality in ICMP patients with inducible ischaemia not eligible for revascularisation [2-6].

The purpose of this study was to determine in 15 patients with ICMP who were not eligible for revascularisation, the markers of mortality analysing Thallium-201 stress/rest single photon emission cardiac tomography (SPECT) and radionuclide ambulatory monitoring (Vest) data with a long-term clinical follow-up.

Methods

Patients

Patients with a median age of 68 years (range 62 - 73) were selected from December 2003 to July 2004 and studied with a median clinical follow-up of 7 years (range 5 - 7) during optimal medical therapy [7].

Stress/rest SPECT

The test was performed after injection of 74 to 148 MBq (2.0 to 4.0 mCi) of Thallium-201 on a 90-degree dual-head gamma-camera (DST-XL; Sophia Medical Vision International, France), equipped with high-resolution, parallel-hole collimators. SPECT images were recorded 2 - 3 minutes after thallium-201 injection, and the baseline images were obtained 3 hours later. Thirty-two projections of 120 seconds were obtained as 64-by-64 matrices over a 180-degree or-
Table 1. Patient Clinical Characteristics

| Patient/age | MI site/LV structural damage | Number of coronary arteries with CAD/ extent of coronary obstructions | ADS extent as % of LV total pixels | ADS rev as % of ADS pixels | New York Heart Association classification | Follow-up results |
|-------------|-----------------------------|------------------------------------------------------------------|-----------------------------------|---------------------------|------------------------------------------|------------------|
| 1/62        | Ant                         | 3/3 by-pass/occluded only graft to LAD                           | 45                                | 9                         | 2                                         | N-SURV (Fatal MI) |
| 2/62        | Ant/prior LV aneurysm resection | 2/occluded LAD/ LCX with 90% stenosis                           | 60                                | 2                         | 3                                         | N-SURV (HF)      |
| 3/69        | Ant, Inf, Lat               | 3/patent stent to RCA and LCX, LAD with 50% stenosis            | 49                                | 0                         | 3                                         | SURV             |
| 4/76        | Ant, Inf                    | 1/occluded stent to LAD                                         | 29                                | 55                        | 3                                         | SURV             |
| 5/74        | Ant, Inf, Lat/LV aneurysm   | 1/occluded LAD                                                  | 11                                | 0                         | 2                                         | N-SURV (HF)      |
| 6/74        | Ant                         | 3/3 by-pass with only occluded graft to LAD                     | 25                                | 10                        | 3                                         | N-SURV (HF)      |
| **7/78      | Ant                         | 1/LAD with 30% stenosis                                         | 15                                | 82                        | 2                                         | SURV             |
| 8/72        | Inf/valvular aortic stenosis | coronary arteries with minimal obstructions                     | 8                                 | 0                         | 2                                         | SURV             |
| 9/53        | Ant, Inf, Lat               | coronary arteries with minimal obstructions/vasospastic angina   | 22                                | 0                         | 2                                         | SURV             |
| 10/50       | Inf                         | ectatic LAD                                                     | 7                                 | 0                         | 2                                         | SURV             |
| 11/62       | Ant, Inf                    | coronary arteries with minimal obstructions                     | 20                                | 5                         | 2                                         | SURV             |
| **12/67     | Ant                         | 3/3 by-pass with only 2 occluded grafts                          | 28                                | 5                         | 3                                         | N-SURV (HF)      |
| *13/68      | Ant, Lat                    | 3/severe stenosis not eligible for revascularisation            | 47                                | 17                        | 3                                         | N-SURV (HF)      |
| *14/68      | Ant, Lat, Inf               | 1/patent stent to RCA                                           | 27                                | 0                         | 2                                         | N-SURV           |
| 15/64       | Ant                         | 1/occluded LAD                                                  | 21                                | 0                         | 2                                         | SURV             |

*Implantable cardioverter-defibrillator (ICD), ** permanent pacemaker implantation for sinus node dysfunction; coronary artery disease (CAD), myocardial infarction (MI), anterior (Ant), inferior (Inf), lateral (Lat), left anterior coronary artery (LAD), left circumflex coronary artery (LCX), right coronary artery (RCA), heart failure (HF).
bit, with an acquisition zoom of 1.33 (pixel size, 6.8 x 6.8 mm) [8]. Bull’s eye polar maps were obtained from SPECT and the abnormal defect size (ADS) quantified as a percentage of the entire left ventricle (LV) surface. The ADS were evaluated visually [9] and as a percentage of total LV pixels and reversibility (rev) was evaluated as a percentage of ADS pixels [10]. All images were interpreted by 2 independent observers.

Radionuclide angiography

Within 2 - 4 weeks following SPECT, the in vivo labelling of red blood cells was performed with 555 MBq (15 mCi) of Technetium-99m-sestamibi using the gamma camera (DST-XL; Sophy Medical Vision International, France) equipped with an all-purpose collimator to determine the gated equilibrium blood pool analysis (MUGA) [11] and ejection fraction (EF) for each subject. The patients were placed in the supine position, with the camera in a 30- to 45-degree left oblique projection, with a 5- to 10-degree caudal tilt. Images were gated at 16 frames/cycle by using an R-wave trigger, and 350,000 counts were obtained for each frame, with a zoom factor of 2 in a 64-by-64 matrix. LV EF was calculated by using standard, automatic, commercially available software (Sophy NXT, Software revision 2.01, Sophy Medical Vision International).

Vest recordings

Immediately after MUGA, the Vest garment was placed over the subject’s chest. The Vest detector (Capintec, Inc., 6 Arrow Road Ramsey, NJ, 07446, USA) was positioned under...
the gamma camera control as previously described in detail [12]. The Vest radionuclide recorder was embedded on the garment worn by patients during daily activities. The EF was calculated continuously with a Holter digital recorder using the formula of end-diastolic volumes per second (EDV/s) counts-end-systolic volumes per second (ESV/s) counts/EDV/s counts-background/s counts x 100. The peak ejection rate (PER), obtained from the systolic phase of the time-activity curve, determined the maximum rate of LV emptying, which was measured as EDV/s. The peak filling rate (PFR), calculated from the diastolic phase of the time-activity curve, revealed the maximum rate of filling in the initial rapid filling period as EDV/s. The Vest recording was ambulant in all patients. All values were recorded simultaneously, including heart rate (HR), ST trends and arrhythmias, under resting conditions (rest) and during exercise. The exercise regimen included climbing the same set of stairs located outside the hospital. As a result, the exercise oxygen uptake was uniform in all of the study subjects.

**Severity of CAD**

Severity of coronary artery disease (CAD) was graded dichotomously on a scale from 0 to 1 (severe CAD = 1, in presence of occlusion of coronary bypass, Stent occlusion or triple vessel disease, moderate CAD = 0, in presence of

| N-SURV | SURV | N-SURV vs. SURV |
|--------|------|----------------|
| rest   | P    | exercise       | rest | P   | exercise | rest P | exercise P |
| HR/bpm | 88 ± 11 | 0.2 | 97 ± 17 | 83 ± 12 | 0.001 | 106 ± 10 | 0.4 | 0.2 |
| EDV(mL) | 105 ± 5 | 0.2 | 97 ± 16 | 102 ± 5 | 0.7 | 105 ± 22 | 0.2 | 0.4 |
| ESV(mL) | 80 ± 8 | 0.02 | 65 ± 20 | 65 ± 11 | 0.02 | 52 ± 16 | 0.008 | 0.2 |
| % EF | 25 ± 7 | 0.01 | 34 ± 10 | 38 ± 9 | 0.01 | 50 ± 13 | 0.01 | 0.02 |
| PFR(edv/s) | 1.3 ± 0.3 | 0.01 | 1.9 ± 0.6 | 1.3 ± 0.4 | 0.01 | 2.7 ± 0.9 | 0.9 | 0.06 |
| PER(edv/s) | 1.4 ± 3 | 0.01 | 2 ± 0.6 | 2.3 ± 0.6 | 0.01 | 3.3 ± 0.7 | 0.003 | 0.003 |

**Figure 2.** Compared to SURV patients, N-SURV patients showed lower exercise PERs with minimally overlapping values.
Follow-up

All patients were followed for a median of 7 years, (range 5 - 7.3 years) with a median of 14 medical visits (range 4 - 18) and a median of 6 hospital readmissions (range 4 - 10) for clinical instability.

Statistical analyses

Tests were performed using a MedCalc Software (Brockstraat 52, 9030 Mariakerke, Belgium). The patients ages, Vest recording time and the follow-up duration were analysed as the median ± interquartile ranges; the SPECT, Vest and follow-up results as the means ± standard deviation and, when necessary, with unpaired or paired t-tests, Bland-Altman plots, receiver operating characteristic (ROC) curves, Cox stepwise proportional-hazards regression and Kaplan-Meier analyses. A P-value less than 0.05 was considered statistically significant. This investigation conforms with the principles outlined in the Declaration of Helsinki. A formal ethics review committee approved this protocol of study, and all subjects provided written informed consent to participate in the study.

Results

Stress/rest SPECT

The SPECT documented ADS and rev ADS of the extent of a mean of 28 ± 16% and 12 ± 24% pixels, respectively. The extent of ADS and the severity of the CAD were significantly correlated (r = 0.66, P < 0.008). When non-survivor patients (N-SURV) and survivor patients (SURV) were compared, the ADS extent did not differ significantly (35 ± 17 vs. 21 ± 5; pixels, p > 0.05). ADS rev was documented in 71% (5/7) and 37% (3/8) of N-SURV and SURV cases, respectively (P > 0.05). Detailed indications of patients clinical characteristics, the SPECT scan results, CAD severity and NYHA class are described in Table 1.

Radionuclide angiography

EFs recorded with Vest and MUGA values (31 ± 10% vs. 29 ± 10%, P > 0.05) did not differ, with a mean difference of only 3% on the Bland-Altman plot. Vest recordings lasted for a median time of 251 min (range 168 - 275). During Vest recordings, in N-SURV patients, only exercise heart rates HRs and exercise EDVs did not increase from rest, a representative example is given in Figure 1; in SURV patients, only exercise EDVs did not increase from rest; at rest, N-SURV showed lower PERs and EFs and higher ESVs compared with SURV; at peak exercise, N-SURV showed lower PERs and EFs and higher ESVs compared with SURV; at peak exercise, N-SURV showed lower PERs and EFs compared with SURV. In SURV patients, the exercise PER changes correlated with the exercise PFR changes (r = 0.71, P < 0.04), but this was not the case in N-SURV patients (r = 0.66, P > 0.05). When using the Vest, neither life-threatening arrhythmias nor significant ST depression or angina episodes were recorded. All of the Vest results are summarised in detail in Table 2.

CAD severity

Severe CAD characterised 86% (6/7) and 25% (2/8) of the
N- SURV and SURV patients, respectively (P < 0.04).

Follow up

Heart failure was observed in 47% (7/15) of patients during follow up. Overall, 1 patient died of fatal myocardial reinfarction after 6 months, and 6 patients died of heart failure after a median of 5.8 years (range 5 - 7 years). Among the N-SURV patients, only two underwent the implantation of a cardioverter defibrillator (ICD), and only 1 was treated with a permanent pacemaker for sinus node dysfunction (SND). Among the SURV patients, only 1 patient was treated with the implantation of a permanent pacemaker for SND. There was no indication for the treatment of any patient with a biventricular pacemaker.

In the Cox proportional hazards regression model, which allows for the analysis of the effects of several risk factors on survival, the exercise PERs were the only significant predictive measures of mortality (b = -0.018, P = 0.02, relative hazard ratio = 0.98, % confidence interval (CI) 0.97 to 0.99). Resting and exercise EFs and PFRs, resting PERs on Vest recordings, the angiographic extent of CAD and the extent of ADS and ADS rev (ischaemia) on thallium-201 SPECT were not predictive of mortality. The results did not change after adjustment for the functional capacity measured by NYHA class, age and established cardiovascular risk factors (P > 0.05 for all). Compared to SURV patients, N-SURV patients showed significantly lower PERs with a minimal overlapping of the values (2 ± 0.5 vs. 2.7 ± 0.4 EDV/s, P = 0.003, 95% CI of the difference 0.4 to 1.9, Fig. 2). Analysing the relationship between exercise PERs and death also with ROC curves, exercise PERs showed under the ROC curve an area of 0.89, P = 0.0001, with a criterion value < than 3 EDV/s. This cutoff value stratified individuals in the Kaplan-Meier survival curve analysis with respect to mortality (Fig. 3).

Discussion

The finding of low exercise PER values resulted the strongest predictor of mortality. Because the EF [13, 14] is the most used prognostic parameter in ICMP in clinical practice, these results require further consideration. In healthy hearts, an enhanced relaxation allows rapid filling and increased contractility. This observation constitutes the basis of the Frank-Starling law, which asserts that the force of the LV contraction is a function of the end-diastolic length of the cardiac muscle, which is strongly related to the EDV increase [15]. Conversely, in both N-SURV and SURV patients, EDVs did not increase accordingly to the workload increment on exercise. Only in N-SURV, the exercise PERs and exercise PFRs, representing rapid LV emptying and relaxation and filling, did not interact. In N-SURV, in addition, the exercise PERs and EFs were significantly lower with respect to SURV. This phenomenon indicated thus the end-stage failure of the Frank-Starling mechanism with exhausted inotropic reserve in N-SURV patients [16]. The evaluation of PER during daily life activity may therefore be an adjunct parameter to EF values for the indication of multiple classes of drugs or drugs with combined effects to increase the output and decrease the filling pressure [17] in patients predisposed to heart failure, which causes significant morbidity and carries a 50% 5-year mortality [18]. Moreover, this study began in 2003 and 2004, when the indications for ICD treatment differed from the currently used criteria [19]. Practice surveys have shown a persistent under-utilisation of ICD treatment. For every ICD implant in European countries, there are four implants in the United States. This disparity is attributable to the relative paucity of diagnostic resources rather than the use of different guidelines [20]. Vest recording of LV function parameters during daily activities could be a useful technique for better tailoring medical therapy and for improving decision making for the potentially lifesaving ICD implantation in certain patients not eligible for revascularisation.

Conclusions

The exercise PER reduced values are thus an important expression of failure of myocardial contractile reserve and depict the incapacity of the heart to perform rapid contractile adaptations to daily life activities and are related to poor prognosis.

The prognostic value of the PER low response to exercise during daily activities appears thus superior to the exercise EF in patients with ICMP not eligible for revascularisation.

Radionuclide ambulatory monitoring may serve as a valuable adjunct in the non-invasive evaluation of LV function of high selected groups of patients with ICMP who need further cardioprotective actions [21-23] besides optimal medical therapy.

Our study has however some limitations due to the small patient sample. The patient population in our study was also quite heterogeneous for CAD severity, which may explain the depressed PER values. In addition, PER and PFR may vary widely from patient to patient due to patient selection or technical reasons [24]. Despite these limitations, the PER and PFR abnormal values assessed by other authors [25] and those observed in this study are significantly correlated. Our findings thus have a reasonable and consistent clinical validity. However, while very interesting and suggestive these results will need to be confirmed in a much larger trial.

References

1. Yoon DY, Smedira NG, Nowicki ER, Hoercher KJ,
1. Rajeswaran J, Blackstone EH, Lytle BW. Decision support in surgical management of ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2010;139(2):283-293, 293 e281-287.

2. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617-1625.

3. Lin FY, Shaw LJ, Dunning AM, Labounty TM, Choi JH, Weinsaft JW, Koduru S, et al. Mortality risk in symptomatic patients with nonobstructive coronary artery disease: a prospective 2-center study of 2,583 patients undergoing 64-detector row coronary computed tomographic angiography. J Am Coll Cardiol. 2011;58(5):510-519.

4. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, et al. Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv. 2010;75(6):886-891.

5. Abdulla J, Asfeg C, Kofoed KF. Prognostic value of absence or presence of coronary artery disease determined by 64-slice computed tomography coronary angiography: a systematic review and meta-analysis. Int J Cardiovasc Imaging. 2011;27(3):413-420.

6. Blankstein R, Di Carli MF. Integration of coronary anatomy and myocardial perfusion imaging. Nat Rev Cardiol. 2010;7(4):226-236.

7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-235.

8. Vera P, Manrique A, Pontvianne V, Hitzel A, Koning R, Criber H. Thallium-gated SPECT in patients with major myocardial infarction: effect of filtering and zooming in comparison with equilibrium radionuclide imaging and left ventriculography. J Nucl Med. 1999;40(4):513-521.

9. Acampa W, Petretta M, Florimonte L, di Santolo MS, Cuocolo A. Sestamibi SPECT in the detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction: comparison between visual and quantitative analysis. J Nucl Cardiol. 2000;7(5):406-413.

10. Berman DS, Kang X, Gransar H, Gerlach J, Friedman JD, Hayes SW, Thomson LE, et al. Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol. 2009;16(1):45-53.

11. Christian PE, Nortmann CA, Taylor A. Comparison of fully automated and manual ejection fraction calculations: validation and pitfalls. J Nucl Med. 1985;26(7):775-782.

12. Kayden DS, Wackers FJ, Zaret BL. Silent left ventricular dysfunction during routine activity after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1990;15(7):1500-1507.

13. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33(7):1948-1955.

14. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98(21):2282-2289.

15. Katz AM. Ernest Henry Starling, his predecessors, and the “Law of the Heart”. Circulation. 2002;106(23):2986-2992.

16. Komamura K, Shannon RP, Ibara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol. 1993;265(4 Pt 2):H1119-1131.

17. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977;297(1):27-31.

18. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012.

19. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gottemolster LS, Gillinov AM, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiovascular Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1-62.

20. John Camm A, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the ‘enigma’? Europace. 2010;12(8):1063-1069.

21. Hausenloy DJ, Baxter G, Bell R, Botker HE, Davidson SM, Downey J, Heusch G, et al. Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol. 2010;105(6):677-686.

22. Genovese EA, Dew MA, Teuteberg JJ, Simon MA, Kay J, Siegenthaler MP, Bhama JK, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg.
23. Bertoldi EG, Polanczyk CA, Cunha V, Ziegelmann PK, Beck-da-Silva L, Rohde LE. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? J Card Fail. 2011;17(10):860-866.

24. Higuchi T, Taki J, Nakajima K, Kinuya S, Ikeda M, Namura M, Tonami N. Left ventricular ejection and filling rate measurement based on the automatic edge detection method of ECG-gated blood pool single-photon emission tomography. Ann Nucl Med. 2004;18(6):507-511.

25. Clements IP. Combined systolic and diastolic dysfunction in the presence of preserved left ventricular ejection fraction. Eur J Heart Fail. 2005;7(4):490-497.